An analysis of five trials comparing adjuvant AIs to tamoxifen showed the odds for arterial hypertension being 1.31 times higher for patients taking aromatase inhibitor; however, this did not reach statistical significance (OR = 1.31; 95% CI 0.47–3.65). Here, CYP19A1 is linked to Hypertension.